Please login to the form below

Not currently logged in
Email:
Password:

Jakavi

This page shows the latest Jakavi news and features for those working in and with pharma, biotech and healthcare.

Another R&D flop for Incyte, but Jakafi keeps delivering

Another R&D flop for Incyte, but Jakafi keeps delivering

Jakafi is marketed by Incyte in the US and by Novartis (as Jakavi) in other markets, for polycythemia vera and myelofibrosis.

Latest news

More from news
Approximately 6 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The successes of Gilenya, Afinitor/Votubia, Galvus, Tasigna and Jakavi - as well as its generics arm, Sandoz - mean that Novartis is now less than $500m behind Pfizer in second place.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials.

  • NICE and ‘ultra orphans’ NICE and ‘ultra orphans’

    Jakavi, in common with most orphan drugs, was assessed under NICE's existing arrangements, though also in common with rare disease treatments such as Roche's MabThera and Celgene's Revlimid, ... Indeed, producing its final guidance on Jakavi in June,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics